Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?

Area of Science:

• Cardiology
• Pharmacology
• Vascular Medicine

Background:

• Long-term anticoagulation is crucial for patients with mechanical heart valves and atrial fibrillation to prevent thromboembolic events.
• Warfarin is the sole indicated anticoagulant for mechanical prosthetic valves.
• Nonvalvular atrial fibrillation patients at high risk for stroke can utilize newer antithrombotic agents like rivaroxaban, dabigatran, and apixaban.

Purpose of the Study:

• To review current therapeutic strategies for anticoagulation and antiplatelet therapy in patients with complex cardiovascular conditions.
• To highlight the challenges in managing patients requiring both anticoagulation and antiplatelet therapy due to coexisting vascular disease.

Main Methods:

• Literature review of current guidelines and expert opinions on antithrombotic therapy.
• Analysis of indications for anticoagulation (mechanical valves, atrial fibrillation) and antiplatelet therapy (coronary artery disease).

Main Results:

• Specific anticoagulant choices depend on the indication (warfarin for mechanical valves, newer agents for nonvalvular atrial fibrillation).
• Concomitant antiplatelet therapy (aspirin alone or dual therapy with clopidogrel, prasugrel, or ticagrelor) is common in patients with vascular disease.
• The combined risks and benefits of dual antithrombotic therapy are not well-established.

Conclusions:

• Current guidelines for combined anticoagulation and antiplatelet therapy are largely based on expert opinion.
• Further research is needed to define the optimal risk-benefit balance for these complex patient populations.
• Individualized treatment strategies are essential for patients requiring multiple antithrombotic agents.